Clinical trials: Intravenous Administration
Invasive Aspergillosis
F901318 Single Ascending Dose Study in Healthy Male Volunteers
F901318 is a potent new antifungal agent for the treatment of systemic fungal infections. This study will test it for the first time in man with the objective of assessing its safety, tolerability and pharmacokinetic profile.
- Trial name
- NCT02142153
- Testing
- F901318
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- F2G Ltd
Advanced Solid Tumors, Non-Hodgkin's Lymphoma
Study of RH-1 in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
This is a Phase 1, nonrandomized, open-label, dose-escalation study of 3-hour IV infusions of RH-1 administered to patients with advanced solid tumors or non-Hodgkin's lymphoma (NHL).
- Trial name
- NCT00558727
- Testing
- RH-1
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Ulcerative Colitis
Special Drug-Use Surveillance Study on Vedolizumab for IV Infusion 300 mg [Ulcerative Colitis]
The purpose of this survey is to evaluate the long-term safety and effectiveness of vedolizumab for intravenous (IV) infusion 300 milligrams (mg) in ulcerative colitis (UC) patients in the routine clinical setting.
- Trial name
- NCT03824561
- Testing
- Vedolizumab
- Where
- Japan
- Volunteers
- 1,110 people
- Sponsor
- Takeda
Fever
Safety of Intravenous Acetaminophen Vs Placebo for the Treatment of Endotoxin-Induced Fever in Healthy Adult Males
A research study to determine if acetaminophen (APAP) given intravenously (IV-a liquid given through a needle into a vein in your arm) is safe and effective in controlling fever when compared to placebo.
- Trial name
- NCT00493311
- Testing
- IV Acetaminophen, Reference Standard Endotoxin (RSE)
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Mallinckrodt
Malignant Solid Tumors
Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors
Primary Objectives: To determine the maximum tolerated dose (MTD) of SAR125844. To confirm safety profile of SAR125844 when administered as single agent at the MTD.
- Trial name
- SARMET (NCT01391533)
- Testing
- SAR125844
- Where
- 8 sites in United States, France and 2 more
- Volunteers
- 72 people
- Sponsor
- Sanofi
Heart Failure, Congestive, Heart Decompensation
A Study to Develop Additional Safety and Clinical Experience With NATRECOR hBNP (Nesiritide) in the Treatment of Patients With Worsening Congestive Heart Failure Who Require Inpatient Intravenous Therapy With Medications That Influence the Tone and Caliber of Blood Vessels
The purpose of this safety study is to evaluate NATRECOR® hBNP (a recombinant form of the natural human peptide normally secreted by the heart in response to heart failure), in subjects with worsening congestive heart failure…
- Trial name
- NCT00271557
- Testing
- nesiritide
- Volunteers
- 305 people
- Sponsor
- Scios, Inc.
Stomach Neoplasms, Metastatic or Locally Advanced Gastric Cancer
huC242-DM4 Treating Patients With Metastatic Gastric or Gastroesophageal Junction Carcinomas
To assess the response rate of huC242-DM4 given as an intravenous infusion to patients with metastatic or locally advanced gastric or gastroesophageal junction cancer.
- Conditions
- Stomach Neoplasms, Metastatic or Locally Advanced Gastric Cancer, Metastatic or Local Advanced GE Junction Cancer
- Trial name
- NCT00620607
- Testing
- huC242-DM4
- Where
- 4 sites in United States
- Sponsor
- ImmunoGen, Inc.
Healthy Volunteers
A Blinded, Placebo-Controlled Study of the Safety and Pharmacokinetics of Single Doses of Intravenous Deferiprone in Healthy Volunteers
Single center, randomized, double-blind, placebo-controlled, adaptive sequential ascending-dose study for the evaluation of the safety, tolerability, and pharmacokinetics of single doses of deferiprone administered by intravenous…
- Trial name
- NCT01989455
- Testing
- Deferiprone
- Where
- Canada
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- ApoPharma
NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer)
A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors
This is a Phase 1b, 2-part, multi-center, open-label study to evaluate the safety, tolerability, dosimetry, and pharmacokinetics (PK) of [64Cu]Cu-AKY-2519 and/or [225Ac]Ac-AKY-2519, as well as the preliminary anti-tumor activity…
- Conditions
- NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer), ES-SCLC, Small Cell Lung Cancer Extensive Stage
- Trial name
- BActinium-2 (NCT07887971)
- Testing
- [225Ac]Ac-AKY-2519 (therapeutic), [64Cu]Cu-AKY-2519 (imaging)
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- Aktis Oncology, Inc.
Safety, and Tolerability
A Study Evaluating the Safety, Tolerability and Pharmacokinetics of ASY202 in Healthy Adults
A Phase 1 clinical trial to evaluate the pharmacokinetics, relative bioavailability, safety and tolerability of DHE inhalation powder delivered by dry powder inhaler, DHE IV, and DHE nasal spray.
- Trial name
- NCT07226362
- Testing
- DHE inhalation powder low dose administered via dry powder inhaler (DPI) device, DHE inhalation powder high dose administered via dry powder inhaler (DPI) device, DHE injected intravenously (1 mg)
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Aspeya Switzerland SA
Gram-negative Bacterial Infection
Evaluation of Pharmacokinetics, Safety, and Tolerability of Ceftazidime-avibactam in Neonates and Infants.
This study will assess the pharmacokinetics, safety, and tolerability of single and multiple doses of intravenous ceftazidime-avibactam in hospitalized infants and neonates from 26 weeks gestation to 3 months of age.
- Trial name
- NOOR (NCT04126031)
- Testing
- Part A: Single Dose Ceftazidime-Avibactam, Cohorts 1-3, Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3
- Where
- 18 sites in United States, Estonia and 6 more
- Volunteers
- 48 people
- Sponsor
- Pfizer
Synovial Sarcoma, Myxoid Liposarcoma
Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel
The purpose of this expanded access protocol (EAP) is to provide controlled access to Afamitresgene autoleucel, suspension for intravenous infusion that does not meet the commercial release specification (NC afami-cel).
- Trial name
- NCT06617572
- Testing
- Non-conforming afamitresgene autoleucel
- Where
- 11 sites in United States
- Sponsor
- USWM CT, LLC
Healthy
Pharmacokinetic Study of JNJ-42756493 in Healthy Participants
The purpose of this study is to evaluate the absolute bioavailability (the extent to which a drug or other substance becomes available to the body) of JNJ-42756493 following a single 10 milligram (mg) dose as an oral solution…
- Trial name
- NCT02218073
- Testing
- JNJ-42756493 10 mg tablet, JNJ-42756493 10 mg Oral Solution, JNJ-61818549
- Where
- Belgium
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Pelvic Inflammatory Disease
Study Of Azithromycin Intravenous Formulation Against Pelvic Inflammatory Disease (PID) In Japan
Azithromycin had a potent in vitro activities and broad spectrum from typical and atypical bacteria to anaerobes. Azithromycin intravenous formulation demonstrated high efficacy and eradication rate in the western clinical…
- Trial name
- NCT00871494
- Testing
- Azithromycin
- Where
- 31 sites in Japan
- Volunteers
- 76 people
- Sponsor
- Pfizer
Persistent Pulmonary Hypertension of the Newborn
Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn
This study assessed the safety and treatment effect of intravenous (IV) Remodulin as an add-on therapy in neonates with persistent pulmonary hypertension of the newborn (PPHN).
- Trial name
- NCT02261883
- Testing
- IV Remodulin
- Where
- 14 sites in United States
- Volunteers
- 42 people
- Sponsor
- United Therapeutics
Acute Myocardial Infarction
Metoprolol in Acute Myocardial Infarction. A PK/PD Study
The objective of the study was to compare treatment with two different oral formulations of metoprolol, metoprolol immediate release (IR) and metoprolol extended release (CR/XL) in patients with acute myocardial infarction…
- Trial name
- NCT01523054
- Testing
- Metoprolol- Toprol XL, Metoprolol- Lopressor
- Volunteers
- 27 people
- Sponsor
- AstraZeneca
Human Volunteers
A Randomized, Double-blind, Pharmacokinetics Study to Assess Safety, Tolerability of Levetiracetam 45 Minutes Intravenous Infusion During 4 Days of Bid Dosing in Chinese Healthy Volunteers
The part B of N01362 is to assess the pharmacokinetic profile of Levetiracetam 1500 mg intravenous (iv) infusion during repeated dosing in Chinese healthy volunteers.
- Trial name
- NCT01618877
- Testing
- Levetiracetam
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- UCB Pharma
Healthy
A Crossover Study to Assess the Effect of Intravenous Infusion of Piperacillin/Tazobactam on the Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) in Healthy Adult Participants
The main purpose of this study is to evaluate the effect of intravenous (IV) infusions of piperacillin/tazobactam on the pharmacokinetics (PK) of JNJ-63549109 after a single oral dose of lumicitabine in healthy adult participants.
- Trial name
- NCT03441529
- Testing
- Lumicitabine, Piperacillin/Tazobactam
- Where
- Belgium
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Breast Cancer
Intravenous RPR109881 in Male or Female Patients With Advanced Breast Cancer Who no Longer Respond to Anthracycline, Taxane and Capecitabine Treatment
The purpose of this clinical trial is to determine if the investigational drug is able to reduce/shrink advanced breast cancer tumors in patients who no longer benefit from anthracyclines, taxanes and capecitabine.
- Trial name
- NCT00087958
- Testing
- XRP9881
- Where
- 15 sites in United States, Argentina and 13 more
- Volunteers
- 168 people
- Sponsor
- Sanofi
PORTs/Peripheral IVs Complication Rates
Post-Marketing Study to Assess Complication Rates of Oncology Patients With Ports and Peripheral IVs
This study is to collect current information on complications rates of subjects undergoing chemotherapy administration through Ports and peripheral IVs.
- Trial name
- VEINSFORLIFE (NCT02792764)
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- C. R. Bard
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.